[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571374":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":28,"locations":38,"responsibleParty":66,"collaborators":69,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":27,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":27,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":53,"whyStopped":27,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cluster Maintenance TMS","ACTIVE_COMPARATOR","Participants will receive a cluster of treatments consisting of 5 treatments over two consecutive week days (either 2 treatments on day 1 followed by 3 treatments day 2 or vice-versa, based on scheduling)",[13],"Device: Transcranial Magnetic Stimulation",{"label":15,"type":10,"description":16,"interventionNames":17},"Gradual Tapering TMS","Participants will receive a once daily treatment protocol delivered once weekly for 1 month, and gradually tapering the frequency of treatment to 1 treatment every 2 weeks for 2 months",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","Transcranial Magnetic Stimulation","rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.",[9,15],[25,26],"rTMS","iTBS",null,[29,34],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Sean M Nestor, M.D.","CONTACT","416-347-0257","sean.nestor@utoronto.ca",{"name":35,"role":31,"phone":36,"phoneExt":27,"email":37},"Chris B Pople, MSc","416-474-5512","chris.pople@mail.utoronto.ca",[39,52],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":27,"geoPoint":27,"contacts":46},"NOT_YET_RECRUITING","North York","Ontario","M4N 3M5","Canada","CA",[47,48,49],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},{"name":35,"role":31,"phone":36,"phoneExt":27,"email":37},{"name":50,"role":51,"phone":27,"phoneExt":27,"email":27},"Sean M Nestor, MD PhD","PRINCIPAL_INVESTIGATOR",{"facility":5,"status":53,"city":54,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Toronto",{"type":56,"coordinates":57},"Point",[58,59],-79.39864,43.70643,{"lat":59,"lon":58},[62],{"name":63,"role":31,"phone":64,"phoneExt":27,"email":65},"Dara Silver","6474044181","ejsilver@rogers.com",{"type":51,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Dr. Sean Michael Nestor","Principal Investigator",[70,73],{"name":71,"class":72},"Mitacs","INDUSTRY",{"name":74,"class":75},"iMediSync","UNKNOWN","100571374","phase-1-qeeg-brain-signature-of-depression--neuromodulation-induced-recovery-100571374",false,"NCT06719427","qEEG Brain Signature of Depression & Neuromodulation-induced Recovery","Quantitative Electroencephalography to Longitudinally Assess the Functional Brain Signature of Treatment-resistant Depression and Recovery With Therapeutic Neuromodulation","Inclusion Criteria:\n\n* A diagnosis of Depression based on Diagnostic and Statistical Manual (DSM) 5.0 criteria.\n* Receiving a neuromodulation (rTMS) treatment for depression at the HCN\n* Physically healthy\n* Age 18-80, inclusive.\n* Able to provide informed consent and comply with the study protocol.\n* Patients will not be excluded solely based on communication (i.e., non-English speaking) unless they have exclusion criteria that is the cause of the communication difficulties.\n\nExclusion Criteria:\n\n* Moderate substance use disorder or greater severity based on DSM 5.0 criteria and confirmed by a study MD on clinical assessment.\n* Mild and major comorbid medical conditions (as determined by investigators - e.g., neurological diseases, uncontrolled hypertension or diabetes, malignancy)\n* A major comorbid psychiatric disorder (as determined by investigators - e.g., schizophrenia or bipolar disorder) and\u002For psychosis at the time of study enrollment.\n* History of seizure disorder\n* Pregnant","ALL","18 Years","80 Years",{"count":87,"type":88},100,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior. rTMS targets these disruptions to restore network function. To measure these effects, researchers will use dry quantitative EEG (qEEG), a new technology that records brain electrical activity quickly (15 minutes compared to 1 hour for traditional EEG) without the need for gel or lengthy electrode setups. This study will evaluate a novel qEEG activity developed by iMediSync (Republic of South Korea) in patients treated with neuromodulation for depression before, during, and up to 12 months after treatment to see if changes in brain activity to identify patterns associated with symptomatic improvement and relapse risk. Findings could help personalize depression treatments by predicting patient outcomes and optimizing care.",[94],"Major Depressive Diorder",[21,96,97,98,99,100,101,102,103,104,105],"Treatment-resistant Depression","Mood Disorders","Mental Disorders","Depressive Disorder","Depressive Disorder, Major","Depressive Disorder, Treatment-Resistant","qEEG","resting-state connectivity","neuromodulation","brain networks","2025-02-26",{"date":108,"type":109},"2025-03-03","ACTUAL",{"date":111,"type":109},"2025-01-06",{"date":113,"type":88},"2028-01-01",{"name":5,"class":6},2]